ストックスクリーナーアプリを入手
2.81
0.18%
0.005
アフターアワーズ：
2.81
前日終値:
$2.805
開ける：
$2.8738
24時間の取引高:
7,320
Relative Volume:
0.31
時価総額：
$18.72M
収益：
$105.38M
当期純損益:
$17.78M
株価収益率:
1.0524
EPS:
2.67
ネットキャッシュフロー:
$-50.48M
1週間 パフォーマンス:
+0.36%
1か月 パフォーマンス:
+4.85%
6か月 パフォーマンス:
-16.62%
1年 パフォーマンス:
-39.57%
1日の値動き範囲:
$2.68
$2.8738
1週間の範囲:
$2.64
$2.91
52週間の値動き範囲:
$2.30
$4.97
Mei Pharma Inc Stock (MEIP) Company Profile
MEIP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
2.81 | 18.72M | 105.38M | 17.78M | -50.48M | 2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-23 | ダウングレード | Laidlaw | Buy → Hold |
| 2022-03-25 | ダウングレード | Jefferies | Buy → Hold |
| 2022-03-25 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-02-03 | 開始されました | Jefferies | Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-05-29 | 開始されました | SunTrust | Buy |
| 2018-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2018-07-27 | アップグレード | Stifel | Hold → Buy |
| 2018-07-13 | 開始されました | SunTrust | Buy |
| 2016-04-18 | 繰り返されました | Wedbush | Neutral |
| 2015-03-23 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-18 | 繰り返されました | ROTH Capital | Buy |
| 2014-10-16 | 繰り返されました | ROTH Capital | Buy |
| 2014-07-08 | 再開されました | Brean Capital | Buy |
| 2013-10-22 | 繰り返されました | Stifel | Buy |
| 2013-04-15 | 開始されました | Stifel | Buy |
すべてを表示
Mei Pharma Inc (MEIP) 最新ニュース
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
Scientist pleads guilty to stealing trade secrets for Chinese pharma company - Fox28 Savannah
Layoff Tracker: Rentschler’s Cell and Gene Therapy Exit Could Affect Up to 30 - BioSpace
ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, - GuruFocus.com
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study - Wiley Online Library
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
Liquid Mushroom Market is Expected to Rise at CAGR of 6% to Reach US$ 15.74 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
MEI Pharma stock hits 52-week low at $2.4 amid market challenges - Investing.com Canada
MEI Pharma stock hits 52-week low at $2.54 amid market challenges - Investing.com Australia
MEI Pharma (LTS:0JW9) 5-Day RSI : 36.09 (As of Dec. 05, 2024) - GuruFocus.com
MEIP (MEI Pharma) Financial Strength : 7 (As of Sep. 2024) - GuruFocus.com
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MEI Pharma (LTS:0JW9) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Deal Dispatch: Starbucks Explores China Sale, PE Firms Saddle Snack Company With DebtAmcor (NYSE:AMCR), Berry Global Gr (NYSE:BERY) - Benzinga
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul - Benzinga
MEI Pharma Reports Strategic Shift Amid Financial Losses - TipRanks
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
MEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year - TipRanks
MEI Pharma Explores Strategic Sale Amid Cash Preservation Efforts, Reports $26.9M Cash Position | MEIP Stock News - StockTitan
Acute Myeloid Leukemia (AML) Treatment Market in APAC to Grow by USD 305.8 Million from 2024-2028, Driven by High Incidence and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Aardvark Therapeutics, Inc. agreed to acquire rights, title and interest in and to certain assets related to ME-344 from MEI Pharma, Inc. for $62.5 million. - Marketscreener.com
Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews
Stocks to Watch: MEI Pharma, Hawaiian Electric Industries - MarketWatch
MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million - MarketWatch
MEI Pharma postpones special meeting to vote on Infinity deal until July 23 - MSN
MEIP (MEI Pharma) Free Cash Flow per Share : $-7.57 (TTM As of Jun. 2024) - GuruFocus.com
Post Polycythemia Vera Myelofibrosis Market: Holistic - openPR
Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.72 amid market challenges - Investing.com India
MEI Pharma stock hits 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
Acute Myeloid Leukemia Market Trends, Key Drivers, Opportunities, Leading Players And Forecast To 2033 - WhaTech
Histone Deacetylase 2 Industry Forecast (2024-2034) Under Inflation - Apiculture Market: Report ...
Myelodysplastic Syndrome Drugs Market Research Explores Size, Market Competitive Landscape, Business Growth... - WhaTech
Chronic Lymphocytic Leukemia Treatment Market Advancements Highlighted by Comprehensive Analysis, Advanceme... - WhaTech
Follicular Lymphoma Treatment Market Insights Discussed Regarding Size, Trends, and Overview Report 2024-2033 - WhaTech
MEI Pharma reviews strategic options amid fiscal changes - Investing.com India
MEI Pharma confirms continuation of evaluation of strategic alternatives - TipRanks
MEI Pharma Reports Fiscal Year End 2024 Cash Position - The Bakersfield Californian
Mei Pharma Inc (MEIP) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
0.53%
大文字化:
|
ボリューム (24 時間):